Proteomics International Laboratories (ASX:PIQ) validated the use of a plasma protein biomarker to detect endometriosis via the PromarkerEndo diagnosis test, according to a Monday filing with the Australian bourse.
A recent study showed that the test was able to separate healthy individuals with endometriosis patients using the biomarker, the filing said.
Results were published in the journal Human Reproduction, as per the filing.
The company's shares surged past 22% in recent Monday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.